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Abstract
Catalytically inactive CRISPR-associated 9 nuclease (dCas9) can be directed by short guide RNAs 
(gRNAs) to repress endogenous genes in bacteria and human cells. Here we show that a dCas9-
VP64 transcriptional activation domain fusion protein can be directed by single or multiple 
gRNAs to increase expression of specific endogenous human genes. These results provide an 
important proof-of-principle that CRISPR-Cas systems can be used to target heterologous effector 
domains in human cells.
Clustered regularly interspaced short palindromic repeats (CRISPR) systems from bacteria1 
have enabled the development of RNA-guided nuclease technology for targeted genome 
editing2–7. The S. pyogenes CRISPR-associated 9 nuclease (hereafter Cas9) can be directed 
by a ~100 nt single guide RNA (sgRNA) to a target genomic DNA sequence that is 
complementary to the first 20 nts of the sgRNA and flanked by a protospacer adjacent motif 
(PAM) sequence of the form NGG4,5. RNA-mediated recruitment of a catalytically inactive 
mutant form of Cas9 (referred to as dCas9) can induce repression of endogenous genes in 
bacterial and human cells8,9. In addition, fusions of dCas9 to effector domains have been 
used to activate reporter genes in E. coli and human cells9,10 and to repress endogenous 
genes in human cells10. Here we sought to determine whether dCas9-based transcriptional 
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activators could regulate endogenous gene expression in human cells using single and 
multiple sgRNAs.
To do this, we constructed a dCas9-VP64 fusion protein consisting of the synthetic VP64 
activation domain11 linked to the carboxy-terminus of the catalytically inactivated dCas9 
protein (Fig. 1a; Online Methods) and tested the ability of this fusion to activate expression 
of the human VEGFA gene. dCas9-VP64 protein was targeted to specific sites in the genome 
of human cells using 16 pre-validated sgRNAs (Supplementary Results and Supplementary 
Table 1) designed to bind sequences within three DNase I hyper-sensitive sites (HSSs) 
located upstream, downstream or at the VEGFA gene transcription start site (Fig. 1b). 15 of 
these 16 sgRNAs (designated V1-V16) induced significant increases in VEGFA protein 
expression when co-expressed with dCas9-VP64 in human 293 cells (Fig. 1c). Expression of 
a codon optimized dCas9-VP64 did not enhance the level of VEGFA activation observed 
(Supplementary Fig. 1). Expression of each of the 16 sgRNAs alone, dCas9-VP64 alone, or 
dCas9-VP64 together with an “off-target” sgRNA designed to bind an EGFP reporter gene 
sequence all failed to induce elevated VEGFA expression (Fig. 1c). In addition, experiments 
with a subset of three sgRNAs demonstrate that activation depends on the presence of the 
VP64 domain in the dCas9-VP64 fusion (Supplementary Results).
We next tested whether RNA-guided activators could also induce expression of the human 
NTF3 gene. To do this, we used six sgRNAs targeted to sequences within a predicted DNase 
HSS in the human NTF3 promoter and codon-optimized dCas9-VP64 (Fig. 1d; Methods). 
All six sgRNAs induced significant increases in NTF3 transcript levels (Fig. 1e) with mean 
levels of activated expression varying over a four-fold range. Experiments with a subset of 
three sgRNAs showed that activation depends on the VP64 domain (Supplementary 
Results). Decreasing the amounts of sgRNA and dCas9-VP64 expression plasmids 
transfected resulted in less activation of the NTF3 gene (Fig. 1e), demonstrating a dose-
dependent effect.
We envisioned that expression of multiple guide RNAs in a single cell might enable 
synergistic activation of endogenous gene targets as recently described for TALE-based 
activators12,13, thereby enabling combinatorial control of endogenous gene expression over 
a wide dynamic range. Co-expression of dCas9-VP64 with four sgRNAs (V1, V2, V3 and 
V4) as well as with subsets of three of these four sgRNAs induced synergistic activation of 
VEGFA protein expression (i.e.—levels of expression significantly greater than the 
expected additive effects of individual activators) (Fig. 2a). Similarly, co-expression of 
dCas9-VP64 with three sgRNAs (N4, N5, and N6) and all possible pairs of these sgRNAs 
led to large increases in NTF3 expression with three of the four combinations yielding a 
mean NTF3 mRNA level greater than the expected additive effects of the individual 
activators (Fig. 2b). Because synergy is mediated by binding of multiple activators to a 
single promoter, our results strongly suggest that multiple sgRNA/dCas9-VP64 complexes 
can function efficiently together in a single cell.
Our experiments define an RNA-guided activator platform that can be easily used to induce 
expression of endogenous genes in human cells. 21 of 22 sgRNAs tested successfully 
induced significant gene activation at the VEGFA and NTF3 gene promoters (although these 
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activators showed substantial variability in activity even when targeted to the same locus 
(Supplementary Discussion)). However, the magnitude of VEGFA and NTF3 gene 
expression increases induced by our dCas9-VP64 activators generally appeared to be lower 
than what we previously observed using VP64-based TALE activators at these same 
endogenous genes.12 Larger-scale testing will be needed to more definitively determine the 
relative success rates and potencies of RNA-guided activators and TALE-based activators in 
human cells.
An important priority for future experiments will be to define the extent of off-target effects 
induced by RNA-guided activators. sgRNA-guided Cas9 nuclease can induce off-target 
mutations at sites that differ by as many as five positions from the on-target sequence in 
human cells but bona fide off-target sites can be difficult to predict14. However, although 
nucleases can in principle alter the DNA sequence of any off-target site, a transcriptional 
activator may not always induce changes in gene expression when it binds to an off-target 
site. Consistent with this, we note that a recent study found minimal, if any, changes in gene 
expression changes in human cells (as measured by RNA-Seq) induced by an RNA-guided 
dCas9-KRAB repression domain fusion10. Additional studies will be needed to determine 
whether this high degree of specificity is a general property of RNA-guided dCas9 fusions.
In summary, our results (and those recently reported by others10) provide proof-of-principle 
that heterologous effector domains can be fused to dCas9 without disrupting its ability to 
complex and function with sgRNAs in mammalian cells. These findings open the door to 
fusion of dCas9 to other novel effector domains (e.g.--histone modifying enzymes, 
modifiers of DNA methylation). The simplicity of sgRNA-mediated targeting together with 
the ability to recruit dCas9 fusions in multiplex fashion should enable important applications 
of these tools for biological research and synthetic biology.
Online Methods
Construction of sgRNA expression plasmids
Pairs of DNA oligonucleotides encoding the variable 20 nt sgRNA targeting sequences were 
annealed together to generate short double-strand DNA fragments with 4bp overhangs 
(Supplementary Table 2). These fragments were ligated into BsmBI-digested plasmid 
pMLM3636 to yield DNA encoding a chimeric +103 single-chain guide RNA3,5 under the 
expression of a human U6 promoter. The pMLM3636 plasmid and its full DNA sequence 
are available from Addgene (http://www.addgene.org/crispr-cas).
Construction of dCas-VP64 expression plasmids
DNA encoding the Cas9 nuclease harboring inactivating D10A/H840A mutations (dCas9) 
was amplified by PCR from plasmid pMJ841 (Addgene plasmid #39318) using primers that 
add a T7 promoter site 5’ to the start codon and a nuclear localization signal at the carboxy-
terminal end of the Cas9 coding sequences and cloned into a plasmid containing a CMV 
promoter as previously described3 to yield plasmid pMLM3629. Oligonucleotides encoding 
a triple FLAG epitope were annealed and cloned into XhoI and PstI sites in plasmid 
pMLM3629 to generate plasmid pMLM3647 expressing dCas9 with a C-terminal flag 
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FLAG tag. DNA sequence encoding a Gly4Ser linker followed by the synthetic VP64 
activation domain was introduced downstream of the FLAG-tagged dCas9 in plasmid 
pMLM3647 to yield plasmid pSL690. The D10A/H840A mutations were also introduced by 
QuikChange site-directed mutagenesis (Agilent) into plasmid pJDS246, which encodes a 
FLAG-tagged Cas9 sequence that has been codon optimized for expression in human cells, 
to yield plasmid pMLM3668. DNA sequence encoding the Gly4Ser linker and the VP64 
activation domain were then cloned into pMLM3668 to yield a codon-optimized dCas9-
VP64 expression vector named pMLM3705. The full amino acid sequence of the dCas9-
VP64 protein is shown in Supplementary Figure 6.
Cell culture and transfection
Human Flp-In T-Rex HEK293 cells were obtained from Life Technologies and cultured and 
transfected as previously described12. Cells were tested every two weeks for mycoplasma 
contamination. Briefly, all transfections were performed in triplicate using Lipofectamine 
LTX (Life Technologies). For transfections involving regulation of VEGFA, 160,000 cells 
were seeded into 24 well plates the day before transfection. 250 ng of plasmid encoding 
VEGFA-targeted sgRNA, 250 ng of plasmid encoding dCas9-VP64 or recoded dCas9-VP64, 
and 30 ng pmaxGFP plasmid (Lonza) were co-transfected using 0.5 µl PLUS reagent and 
2.65 µl Lipofectamine LTX. For synergy experiments, the amount of each sgRNA was kept 
constant such that all transfections contained 62.5 ng of each sgRNA and empty U6 
promoter plasmid was used to fill up to a total of 250 ng. For transfections involving 
regulation of NTF3, 350,000 cells were seeded in 12 well plates the day before transfection. 
100, 250, or 500 ng of plasmid encoding NTF3-targeted sgRNA, 250ng or 500ng of plasmid 
encoding codon optimized dCas9-VP64, and 60 ng pmaxGFP plasmid (Lonza) were co-
transfected using 1 µl PLUS reagent and 2.1, 2.65, or 5.1 µl Lipofectamine LTX, 
respectively. For synergy experiments, the amount of each sgRNA was kept constant such 
that all transfections contained 83.3 ng of each sgRNA and empty U6 promoter plasmid was 
used to fill up to a total of 500 ng.
Enzyme-Linked Immunoblot Assays of VEGFA protein
Culture medium of Flp-In T-Rex HEK293 cells transfected with plasmids encoding VEGFA-
targeted sgRNA and dCas9-VP64 was harvested 40 hours post-transfection and VEGFA 
protein expression was measured by ELISA as previously described12.
Quantitative reverse-transcription polymerase chain reaction (qRT-PCR)
Total RNA from Flp-In T-Rex HEK293 cells transfected with plasmids encoding NTF3-
targeted sgRNAs and codon-optimized dCas9-VP64 was isolated two days post-transfection 
using the PureLink RNA Mini Kit (Ambion) and treated with TurboDNA-Free (Ambion) 
according to manufacturer’s instructions. NTF3 mRNA levels were measured by 
quantitative RT-PCR using a Taqman assay as previously described12
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. RNA-guided activation of endogenous human genes
(a) Schematic depicting recruitment of dCas9-VP64 fusion protein to a specific genomic 
target sequence by an sgRNA. (b) 16 sgRNAs targeted to the endogenous human VEGFA 
gene promoter. Red arrows represent the first 20 nts of the sgRNA pointing 5’ to 3’. Grey 
bars indicate DNaseI hypersensitive sites previously defined in human 293 cells15, 
numbered relative to the transcription start site (black arrow). (c) Activation of VEGFA 
protein expression in 293 cells by various sgRNAs, each expressed with (blue bars) or 
without (red bars) dCas9-VP64. Asterisks indicate samples that are significantly elevated 
above the off-target control as determined by a paired, one-sided t-test (n = 3, P < 0.05); 
error bars represent s.e.m. (d) Six sgRNAs targeted to the endogenous human NTF3 gene 
promoter represented as in (b) Grey line indicates region of potential open chromatin 
identified from the ENCODE DNaseI hypersensitivity track on the UCSC genome browser 
with the thicker part of the bar indicating the first transcribed exon. Numbering shown is 
relative to the transcription start site (black arrow). (e) Activation of NTF3 gene expression 
by RNA-guided dCas9-VP64 in 293 cells. Relative expression of NTF3 mRNA is shown for 
293 cells co-transfected with the indicated amounts of codon-optimized dCas9-VP64 and 
NTF3 -targeted sgRNA expression plasmids. Asterisks indicate samples that are 
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significantly greater than the off-target sgRNA control as determined by a paired, one-sided 
t-test (n = 3, P < 0.05); error bars represent s.e.m.
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Figure 2. Synergistic activation of the endogenous human VEGFA and NTF3 genes by RNA-
guided activators
(a) Multiplex sgRNA expression induces synergistic activation of VEGFA protein 
expression by dCas9-VP64 protein. The calculated sum of mean VEGFA protein expression 
induced by individual sgRNAs is shown for each combination as green bars. Asterisks 
indicate all combinations that were found to be significantly greater than the expected sum 
as determined by an analysis of variance (ANOVA) (n = 3, P < 0.05). Error bars represent 
standard errors of the mean. (b) Multiplex sgRNA expression induces increased activation 
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of NTF3 mRNA expression by dCas9-VP64 protein. Relative expression of NTF3 mRNA is 
shown for 293 cells in which the indicated individual or combinations of sgRNAs were co-
expressed with dCas9-VP64. The calculated sum of mean NTF3 mRNA expression induced 
by individual sgRNAs is shown for each combination as green bars. P values were 
determined by a paired, one-sided T-test (n = 3). Error bars represent standard errors of the 
mean.
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